Miura, Shinji et al. published their research in Cancer Letters (Shannon, Ireland) in 1998 | CAS: 56632-83-8

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Application of 56632-83-8

Antitumor activity of a novel orally effective nucleoside, 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine was written by Miura, Shinji; Yoshimura, Yuichi; Endo, Mikari; Machida, Haruhiko; Matsuda, Akira; Tanaka, Motohiro; Sasaki, Takuma. And the article was included in Cancer Letters (Shannon, Ireland) on July 3,1998.Application of 56632-83-8 The following contents are mentioned in the article:

The antitumor activity of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine (thio-FAC) was evaluated. Thio-FAC inhibited the in vitro growth of various human cancer cell lines, particularly the growth of cell lines established from gastric and colorectal carcinomas, while its oxy-type congener 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)cytosine (FAC) showed little or no activity against such solid cancer cell lines. Thio-FAC showed remarkable antitumor effects against human tumors s.c. implanted in nude mice and was highly effective even by oral administration. Thio-FAC was less susceptible to deamination by cytidine deaminase than FAC and 2′-deoxy-2′,2′-difluorocytidine (gemcitabine) and therefore is a promising drug for cancer chemotherapy. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Application of 56632-83-8).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Application of 56632-83-8

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8